Document Detail


Growth hormone and cardiac function.
MedLine Citation:
PMID:  10790587     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Impaired cardiovascular function, which may reduce life expectancy, has recently been demonstrated both in GH deficiency and excess. Moreover, experimental and clinical studies support the evidence implicating GH and/or IGF-I in the regulation of heart development. The existence of a specific acromegalic cardiomyophathy characterized by myocardial hypertrophy with interstitial fibrosis, lympho-mononuclear infiltration and areas of monocyte necrosis which often result in biventricular concentric hypertrophy has been recenty demonstrated. By contrast, patients with childhood or adulthood-onset GH deficiency (GHD) present with abnormalities of structure and function of the left ventricle. In these patients, a significant increase in the vascular intima-media thickness and an increased number of atheromatous plaques have also been reported. The abnormalities of cardiovascular system could be partially reverted by suppressing GH and IGF-I levels in acromegaly or after GH remplacement therapy in GHD patients. The evidence that GH is able to increase cardiac mass suggested its use in the -treatment of chronic heart failure of diverse etiologies. GH administration was -demonstrated to induce an improvement in hemodynamics and clinical status in some patients. Although these data should be confirmed in double-blind placebo controlled studies in larger series, the promising results open new perspectives for GH treatment in humans.
Authors:
G Lombardi; C Di Somma; P Marzullo; G Cerbone; A Colao
Related Documents :
11515307 - Ultrastructural and molecular changes in the left and right ventricular myocardium asso...
2427067 - Morphometric analysis of collagen network and plasma perfused capillary bed in the myoc...
2934327 - Detection of hypertensive left ventricular hypertrophy.
2150037 - Diastolic function in left ventricular hypertrophy: clinical and experimental relations...
16271777 - Erectile dysfunction in healthy subjects predicts reduced coronary flow velocity reserve.
16008157 - Restenosis treatment in the drug-eluting stent era.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Annales d'endocrinologie     Volume:  61     ISSN:  0003-4266     ISO Abbreviation:  Ann. Endocrinol. (Paris)     Publication Date:  2000 Feb 
Date Detail:
Created Date:  2000-06-27     Completed Date:  2000-06-27     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  0116744     Medline TA:  Ann Endocrinol (Paris)     Country:  FRANCE    
Other Details:
Languages:  eng     Pagination:  16-21     Citation Subset:  IM    
Affiliation:
Departement of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acromegaly / physiopathology
Cardiac Output, Low / drug therapy
Heart / physiopathology*
Human Growth Hormone / deficiency,  physiology*,  therapeutic use
Humans
Insulin-Like Growth Factor I / physiology,  therapeutic use
Chemical
Reg. No./Substance:
12629-01-5/Human Growth Hormone; 67763-96-6/Insulin-Like Growth Factor I

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Synthesis and local and distant actions of vasoactive peptides
Next Document:  The growth hormone and insulin-like growth factor 1 axis in heart failure.